Certara, Inc.

Certara provides software and technology-enabled services supporting drug development across discovery, preclinical testing, clinical research, regulatory approval, and market access phases. The company's core offerings center on biosimulation and model-informed drug development, enabling pharmaceutical and biotechnology organizations to predict drug behavior and optimize development pathways. Its product portfolio includes the Simcyp physiologically-based pharmacokinetic simulation platform, Phoenix analytical software suite for pharmacokinetic analysis, and clinical data management tools such as Pinnacle 21 for regulatory submissions.

The company operates across multiple segments addressing different stages of the drug development lifecycle. Discovery and development solutions include the Simcyp simulator family and Phoenix platform for pharmacokinetic modeling, as well as Chemaxon tools for chemical design and compound registration. Regulatory and market access offerings encompass CoAuthor for submission assembly, GlobalSubmit for submissions management, and Pinnacle 21 for clinical data standardization and validation. These products serve small molecule and biologics developers globally.

Certara employs approximately 1,487 full-time staff and maintains its headquarters in Radnor, Pennsylvania. The company is incorporated in Delaware and trades on Nasdaq. Operations span North America, Europe, and Asia-Pacific regions, serving pharmaceutical companies, contract research organizations, and regulatory agencies conducting drug development and approval activities.